Skip to main content

Advertisement

Table 3 Per-protocol primary endpoint analysis of treatment responses in cases with Plasmodium falciparum or Plasmodium. vivax for PCR-corrected malaria

From: Efficacy of artemether–lumefantrine and dihydroartemisinin–piperaquine for the treatment of uncomplicated malaria in Papua New Guinea

  AL DHA-PPQ Total P-value
P. falciparum assessed at day 28, n 110 138 248  
 Adequate clinical and parasitological response, n (%) [95% CI] 110 (100) [95.8–100] 138 (100) [96.6–100] 248 (100)
 Early treatment failure, % 0 0 0
 Late clinical failure, % 0 0 0
 Late parasitological failure, % 0 0 0
P. falciparum assessed at day 42, n 106 135 241  
 Adequate clinical and parasitological response, n (%) [95% CI] 104 (98.1) [92–99.7] 135 (100) [96.6–100] 239 (99.2) − 0.11
 Early treatment failure, % 0 0 0
 Late clinical failure, % 0 0 0
 Late parasitological failure, % 1.9 0 0.8
P. vivax assessed day 28, n 23 41 64
 Adequate clinical and parasitological response, n (%) [95% CI] 22 (95.7) [76.03–99.8] 41 (100) [89.3–100] 63 (98.4) 0.18
 Early treatment failure, % 0 0 0
 Late clinical failure, % 0 0 0
 Late parasitological failure, % 4.3 0 1.6
P. vivax assessed day 42, n 19 39 58
 Adequate clinical and parasitological response, n (%) [95% CI] 15 (78.9) [53.9–93.03] 36 (92.3) [78.03–98.0] 51 (87.9) 0.14
 Early treatment failure, % 0 0 0
 Late clinical failure, % 5.3 0 1.7
 Late parasitological failure, % 15.8 7.7 10.3